NCT05446324CompletedPhase 3
SENtinel lymph node mapping with GAllium-68-tilmanocept PET/CT in high/high- intermediate risk endometrial cancer: a proof-of-concept study
Source: EU CTIS (euclinicaltrials.eu) · Last updated 15 Nov 2024
Brief summary (registry, in English)
to evaluate feasibility of 68Ga-tilmanocept PET/CT for SLN mapping in patients with stage I-II high/high-intermediate risk endometrial cancer
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 10 (actual)
- First submitted
- 9 Oct 2024
- Start date
- 15 Nov 2024
- Lead sponsor
- Universitair Medisch Centrum Utrecht
- Diseases
- Endometrial cancer
- NCT number
- NCT05446324
- EU CT number
- 2024-516708-40-00
- EudraCT number
- 2022-001237-37
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 10
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Who cannot take part
Copied verbatim from EU CTIS (euclinicaltrials.eu) and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Pregnancy or current breastfeeding (in women at a ferile age with a possibility of prenancy, confirmation by a pregnancy test is current standard of care); - Prior severe allergic reaction to iodine; - Severe renal insufficiency (stage 3 or 4); - Clinical or radiological evidence of metastatic disease.
Who the study is looking for
- Clinical FIGO 2012 stage I-II high/high-intermediate risk endometrial cancer; - Scheduled for robot-assisted full pelvic and para-aortic staging; - Age ≥18 years and able to provide informed consent.
Age in the registry: 18 years to - · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Universitair Medisch Centrum Utrecht Coordinator of this site? Confirm its status | Utrecht | Netherlands | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.